Filing summary
Entity discrepancy: The request identifies Tuhura Biosciences, Inc., but the supplied Form 10-K is for DelMar Pharmaceuticals, Inc. This summary reflects the filing text. It covers the fiscal year ended December 31, 2013; it is an annual report, not a standalone fourth-quarter report. Financial amounts are in U.S. dollars unless stated otherwise.
Business context and reporting period
DelMar is a development-stage oncology company with no product revenue. Its lead candidate, VAL-083, is being studied in a U.S. Phase I/II trial for recurrent glioblastoma (GBM). VAL-083 is approved in China for chronic myelogenous leukemia and lung cancer, and DelMar holds certain exclusive China commercial rights. On January 25, 2013, DelMar completed a reverse acquisition that made the pre-transaction DelMar (BC) business the accounting predecessor.
Key financial metrics
| Metric | 2013 | 2012 |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $2.343 million | $1.550 million |
| General and administrative expense | $3.952 million | $1.155 million |
| Net loss | $8.291 million | $2.400 million |
| Basic and diluted loss per share | $0.28 | $0.18 |
| Cash used in operating activities | $5.520 million | $0.578 million |
| Cash and cash equivalents at year-end | $4.137 million | $17,782 |
| Working capital | $4.069 million | Deficit of $0.943 million |
| Total assets | $4.319 million | $0.183 million |
| Shareholders’ deficiency | $0.818 million | $1.328 million |
Margins are not meaningful because the company reported no product revenue. Total liabilities include a $4.402 million derivative liability and a $212,561 stock-option liability. The company also reported a $272,372 unsecured loan payable to Valent, including accrued interest; management presented it as long-term. Current accounts payable and accrued liabilities, including related-party payables, totaled $249,487.
Material changes versus the prior comparable period
- Net loss rose by $5.890 million, while operating cash use increased by $4.942 million.
- R&D expense increased 51%, reflecting continued clinical development and higher personnel, intellectual-property, and travel costs. G&A expense increased 242%, including costs related to the reverse acquisition, public-company reporting, and investor relations.
- Cash increased mainly after a 2013 private offering of 13.125 million units for $10.5 million gross proceeds. The filing describes net proceeds of $8.575 million; cash-flow presentation reports $9.640 million of net unit proceeds because of the accounting allocation of offering costs between equity and derivative liabilities.
- The derivative liability increased to $4.402 million from $121,000, largely due to the offering and reverse acquisition. A $1.324 million fair-value gain reduced the reported 2013 loss; changes in this valuation can make reported results volatile.
Outlook, commentary, risks, and unusual items
- Management estimated that year-end cash could fund operations for 12 to 15 months, but said additional equity financing and/or strategic partnerships would be needed. The auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern.
- Management planned to continue GBM dose escalation and anticipated reaching the maximum tolerated dose during 2014. Interim results were early-stage: the filing reports stable disease or tumor regression in 2 of 8 GBM patients and 1 of 6 secondary brain-cancer patients in early dose cohorts; the maximum tolerated dose had not been reached. These are not definitive efficacy findings.
- The company anticipated potential China product sales or royalty revenue, possibly beginning in 2014, through a marketing partner. However, it had not begun generating product revenue, and the timing and amount of any China revenue were uncertain.
- Key risks include dependence on one lead candidate, clinical and regulatory uncertainty, need for additional financing, potential dilution from outstanding securities, reliance on a single clinical-supply manufacturer, and comparatively weak intellectual-property protection in China. The filing also identifies related-party ties to Valent, which is owned by the Chief Scientific Officer.
- Unusual 2013 items included $2.713 million of derivative issuance costs and a $598,000 expense for shares issued to Valent in exchange for reducing certain future royalties. The reverse-acquisition accounting also recorded a $3.732 million adjustment to opening deficit.
- The auditor issued an unqualified opinion on the financial statements with a going-concern emphasis. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is DelMar Pharmaceuticals, Inc., not Tuhura Biosciences, Inc.
- Check the company’s subsequent cash position, operating burn, and access to financing against the 12–15-month runway estimate and going-concern warning.
- Review subsequent clinical-trial enrollment, safety, dose escalation, and efficacy data; distinguish interim observations from evidence sufficient for approval.
- Verify whether China commercialization or licensing generated revenue and whether the supply and marketing arrangements remained in effect.
- Assess potential dilution and valuation volatility from warrants, options, exchangeable shares, and the $4.402 million derivative liability.